Sponsors (45)
Introduced January 9, 2025 by LaMonica McIver · Last progress January 9, 2025
The bill expands and standardizes PAD screening and prevention—likely improving early detection, reducing amputations, and improving equity for vulnerable populations—but it increases federal/state spending and administrative complexity and risks uneven access, capacity strain, and some low‑value use unless carefully implemented and funded.
People with PAD and other chronic vascular conditions (including Medicare and Medicaid beneficiaries and older adults) will be identified and treated earlier, reducing avoidable amputations, cardiac deaths, and long‑term disability.
Medicare and Medicaid beneficiaries will face lower out‑of‑pocket costs and greater access to covered PAD screening and preventive services (Medicare: no Part B deductible; Medicaid: no cost‑sharing), increasing affordability of early detection for low‑income and older adults.
The bill promotes standardized guidance, clinician education, and quality measures (disseminated best practices, defined tests/frequency, and performance incentives), which should improve care consistency and earlier detection across providers.
Expanded coverage, program funding, and higher payment rates will raise federal and state healthcare spending (new federal authorizations, Medicare/Medicaid costs), increasing budgetary outlays and strain on trust funds/taxpayers.
Implementing the new screening programs, payment changes, and quality measures will create administrative and reporting burdens for federal and state agencies, hospitals, and clinicians, raising short‑term operational costs.
Expanded screening may increase demand on specialty vascular services and diagnostic capacity, risking longer wait times and uneven access—especially in rural and underserved areas with limited workforce.
Based on analysis of 6 sections of legislative text.
Funds CDC education, requires Medicare/Medicaid coverage and no‑cost PAD screening for at‑risk people, creates quality measures, and tasks CMMI to test a prevention model.
Creates a coordinated federal effort to prevent avoidable lower‑limb amputations by funding CDC education, expanding Medicare and Medicaid coverage (and waiving cost‑sharing) for specified peripheral artery disease (PAD) screening tests for defined “at‑risk” groups, requiring new quality measures to reduce nontraumatic major amputations, and directing CMMI to test a voluntary amputation‑prevention payment and delivery model. It provides $6 million per year for CDC education (FY2026–FY2030), sets Medicare/Medicaid coverage rules and no‑cost screening for at‑risk beneficiaries (with Medicare changes effective January 1, 2026), and requires HHS to establish screening frequency standards and implement quality reporting changes and CMMI testing within set timeframes.